Combination Regimens with Colistin Sulfate versus Colistin Sulfate Monotherapy in the Treatment of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli
暂无分享,去创建一个
F. Hu | Yan Guo | Yang Yang | Min Hao | Shiann-Ching Wu | Xiaohua Qin
[1] P. Liu,et al. Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. , 2022, The Journal of antimicrobial chemotherapy.
[2] Q. Qu,et al. Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety , 2022, Infection and Drug Resistance.
[3] K. Kaye,et al. Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients , 2021, CPT: pharmacometrics & systems pharmacology.
[4] F. Franceschi,et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. , 2021, International journal of antimicrobial agents.
[5] C. Chao,et al. Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis. , 2021, Surgical infections.
[6] Qiong Lu,et al. A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections , 2021, Frontiers in Medicine.
[7] Yibo Fei,et al. Pharmacokinetics of Colistin in Cerebrospinal Fluid after Intraventricular Administration Alone in Intracranial Infections: Pharmacokinetics of Colistin in CSF. , 2021, International journal of antimicrobial agents.
[8] Evangelos I. Kritsotakis,et al. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems , 2020, Infection.
[9] Y. Doi,et al. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) , 2020, Emerging microbes & infections.
[10] M. Antonelli,et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial , 2019, Critical Care.
[11] Ronald N. Jones,et al. Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) , 2019, Antimicrobial Agents and Chemotherapy.
[12] Y. Doi. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] A. Oliver,et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections , 2019, Clinical Microbiology Reviews.
[14] R. Bonomo,et al. Polymyxins: To Combine or Not to Combine? , 2019, Antibiotics.
[15] F. Hu,et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa , 2019, Antimicrobial Agents and Chemotherapy.
[16] M. Abdelsalam,et al. Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. , 2018, Journal of global antimicrobial resistance.
[17] L. Leibovici,et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.
[18] M. Falagas,et al. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. , 2017, International journal of antimicrobial agents.
[19] K. Yu,et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[20] Brian T. Tsuji,et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. , 2015, The Lancet. Infectious diseases.
[21] V. Miriagou,et al. Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems , 2014, Antimicrobial Agents and Chemotherapy.
[22] T. Hirama,et al. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects , 2011, Current medical research and opinion.
[23] O. Zusman,et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis , 2017, The Journal of antimicrobial chemotherapy.
[24] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .